| EMORY UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120130282 | TARGETING THERAPEUTIC AGENTS - Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents. | 05-24-2012 |
| 20120123205 | ADDITIONAL SYSTEMS AND METHODS FOR PROVIDING REAL-TIME ANATOMICAL GUIDANCE IN A DISGNOSTIC OR THERAPEUTIC PROCEDURE - A system and method for intra-operatively providing anatomical guidance in a diagnostic or therapeutic procedure is disclosed. In embodiments, the system includes multiple light sources configured to emit different frequencies, multiple electronic imaging devices to detect various frequencies of reflected, emitted, or scattered light. The system and method incorporate an optical probe is integral to an endoscopic device or a therapeutic laser system, optically coupled to a light source; a display for displaying at least one visual representation of data; and a controller programmed to generate at least one real-time integrated visual representation of an area of interest and to display the real-time visual representation on the display for guidance during the diagnostic or therapeutic procedure. | 05-17-2012 |
| 20120108650 | MICRO RNA MARKERS AND METHODS RELATED THERETO - The present invention provides methods of diagnosis of Alzheimer's disease including assessing the levels of certain microRNAs in a subject and comparing these to levels in subjects not exhibiting the disease. The identified measurements provide input for improved diagnoses of Alzheimer's disease as compared to certain other forms of dementias, which allows more effective treatment regimens. | 05-03-2012 |
| 20120108510 | METHODS OF IMPROVING BEHAVIORAL THERAPIES - This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy. | 05-03-2012 |
| 20120107902 | Processes For Forming Amide Bonds And Compositions Related Thereto - The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed. | 05-03-2012 |
| 20120083713 | DEVICE FOR GAUGING A FORCE THRESHOLD AND ENGAGING A TARGET OF INTEREST - The disclosure generally relates to devices and instruments for engaging a target of interest, having a resilient member for gauging a force threshold. The device or instrument may include a tip portion, wherein the tip portion includes a first end portion a having an engaging member configured to engage a target of interest, an opposite, second end portion, and a body portion defined therebetween, the body portion including a resilient member configured to be elastically compressible up to a predetermined maximum compression level. | 04-05-2012 |
| 20120076820 | CD40L VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO - The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject. | 03-29-2012 |
| 20120071539 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST - Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic compositions comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided. | 03-22-2012 |
| 20120059282 | INTERNET-BASED COGNITIVE DIAGNOSTICS USING VISUAL PAIRED COMPARISON TASK - Disclosed are methods for diagnosing declarative memory loss using mouse tracking to follow the visual gaze of a subject taking a visual paired comparison test. Also disclosed are methods for diagnosing dementia such as mild cognitive impairment and Alzheimer's disease. | 03-08-2012 |
| 20120058978 | METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents. | 03-08-2012 |
| 20120040924 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV. | 02-16-2012 |
| 20120029932 | DISPLAY OF PATIENT-SPECIFIC DATA - Systems, methods, and computer-program products identify clinical data corresponding to a plurality of patients located within a common health care delivery unit, and apply one or more rules to at least some of the clinical data using at least one quality and/or safety measure-specific specification. Based on the application of the rules, one or more care indicators corresponding to the plurality of patients are displayed in a single interface, the one or more care indicators indicating whether one or more of the patients is receiving appropriate care. | 02-02-2012 |
| 20120028977 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions - Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed. | 02-02-2012 |
| 20120027666 | POLYOXOMETALATE WATER OXIDATION CATALYSTS AND METHODS OF USE THEREOF - Homogeneous water oxidation catalysts (WOCs) for the oxidation of water to produce hydrogen ions and oxygen, and methods of making and using thereof are described herein. In a preferred embodiment, the WOC is a polyoxometalate WOC which is hydrolytically stable, oxidatively stable, and thermally stable. The WOC oxidized waters in the presence of an oxidant. The oxidant can be generated photochemically, using light, such as sunlight, or electrochemically using a positively biased electrode. The hydrogen ions are subsequently reduced to form hydrogen gas, for example, using a hydrogen evolution catalyst (HEC). The hydrogen gas can be used as a fuel in combustion reactions and/or in hydrogen fuel cells. The catalysts described herein exhibit higher turn over numbers, faster turn over frequencies, and/or higher oxygen yields than prior art catalysts. | 02-02-2012 |
| 20120022086 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS - Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds. | 01-26-2012 |
| 20120022070 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use - Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and conditions, such as inflammation and neurodegenerative disorders. Methods of treating and preventing cancer and other Hsp90 related diseases and conditions are disclosed that include administering to the subject a therapeutically effective amount of an Hsp90 inhibitor. Methods of preparing the novel Hsp90 inhibitors are also provided. | 01-26-2012 |
| 20110319416 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions - Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-E, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed. | 12-29-2011 |
| 20110306579 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D - Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D. | 12-15-2011 |
| 20110305636 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT - Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging). | 12-15-2011 |
| 20110294844 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 12-01-2011 |
| 20110288044 | Modulation of sodium channels by nicotinamide adenine dinucleotide - The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD | 11-24-2011 |
| 20110286919 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor. | 11-24-2011 |
| 20110282587 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY - Described herein are computer-readable storage mediums, methods and systems useful for analyzing samples via mass spectrometry. Aspects described herein include methods for normalizing mass spectrometry data that include providing a reference set of mass spectrometry data obtained from a first external standard sample having one or more isotopic standards, wherein the reference set of mass spectrometry data comprises one or more m/z intensity ratios. Methods described herein are useful for reducing errors based on instrument response and ionization efficiencies and improve reproducibility of data from instrument to instrument and from day to day. | 11-17-2011 |
| 20110282081 | Methods of Preparing 1-Deoxy-Sphingoid Bases and Derivatives Thereof - Novel methods of synthesizing 1-deoxy-sphingoid bases and derivatives are disclosed. The synthesis is achieved from commercially available and inexpensive starting materials. The process includes thioesterification, cross-coupling, and reduction. The process may also include directed epoxidation, regioselective epoxide-opening, hydrogenation, and dihydroxylation. The methods described herein provide 1-deoxy-sphingoid bases and derivatives in high overall yield and high enantiomeric purity. | 11-17-2011 |
| 20110281908 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use - Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors and methods for making these classes are provided herein. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases, such as inflammation and neurodegenerative disorders. Also provided herein are methods of treating and preventing cancer and other Hsp90 related disease. The methods include administering to a subject a therapeutically effective amount of an Hsp90 inhibitor. | 11-17-2011 |
| 20110275839 | COMPOUNDS, INTERMEDIATES, AND METHODS OF PREPARING THE SAME - The present disclosure provides optionally substituted seven-membered ring isomers of naturally occurring carbohydrate compounds, methods of synthesizing these compounds, intermediate compounds, methods of synthesizing the intermediate compounds, and the like. | 11-10-2011 |
| 20110274651 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition - Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds. | 11-10-2011 |
| 20110235884 | Atlas-Assisted Synthetic Computed Tomography Using Deformable Image Registration - Disclosed are systems for and methods of creating a synthetic image by registering a reference or atlas image to a clinical image using both rigid and deformable image registration algorithms. In some embodiments, a synthetic computed tomography (CT) image may be created by registering an atlas CT image to a clinical image such as an MR scan. Rigid registration in some embodiments may be followed by a smoothing B-spline transform algorithm with a mutual information similarity metric and an optimizer; followed then by an image signal intensity algorithm with displacement vectors at each voxel and diffeomorphic transformations. | 09-29-2011 |
| 20110230361 | PROSTATE CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL - Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer. | 09-22-2011 |
| 20110224752 | MICROELECTRODE STIMULATION FOR TREATMENT OF EPILEPSY OR OTHER NEUROLOGIC DISORDER - Methods for treating a neurologic disorder by neurostimulation. The stimulation may be applied using electromagnetic energy. In certain embodiments, distributed electrical stimulation is applied to a target site of the brain in an ongoing fashion. A microelectrode array may be used to provide the distributed electrical stimulation. The method may also comprise the detection of electrophysiologic signals from the brain. These detected signals may be analyzed and used for closed-loop feedback of the neurostimulation. Also provided are systems for neurostimulation and software for operating such systems. | 09-15-2011 |
| 20110206699 | Methods for the Treatment of Graft-Versus-Host Disease - Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject. | 08-25-2011 |
| 20110189236 | Methods and Compositions for the Display of Polypeptides on the Pili of Gram-Positive Bacteria - Provided herein are methods and compositions for the display of polypeptides of interest on the tip of pili of Gram-positive bacteria. According to the present invention, the polypeptide of interest is amino terminal to a Gram-positive bacterial pilus tip protein or an active variant or fragment thereof, wherein the active variant or fragment comprises a cleaved cell wall sorting signal (CWSS) motif. The Gram-positive bacterium displaying a polypeptide of interest on the tip of pili that are disclosed herein are useful, for example, in methods for immunizing a subject with an antigen and methods for removing contaminants from a composition. | 08-04-2011 |
| 20110144196 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF - Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. | 06-16-2011 |
| 20110144096 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 06-16-2011 |
| 20110129496 | Use of mTOR Inhibitors to Enhance T Cell Immune Responses - It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog. | 06-02-2011 |
| 20110105343 | Systems Biology Approach Predicts Immunogenicity of Vaccines - A major challenge in vaccinology is to prospectively determine vaccine efficacy. Disclosed herein are methods and compositions for identifying early expression “signatures” that predicted immune responses in humans vaccinated with a vaccine. | 05-05-2011 |
| 20110085974 | SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue. | 04-14-2011 |
| 20110077293 | GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 03-31-2011 |
| 20110070166 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 03-24-2011 |
| 20110064675 | ELEMENTAL IRON NANOPARTICLES - Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free environment to form coated iron particles. An average diameter of the coated iron particles is between 5 nm and 25 nm. The biocompatible coating can functionalized with cell-specific agents for use as diagnostic and therapeutic agents. | 03-17-2011 |
| 20110064656 | Methods of Determining Renal Function using Technetium-99m Tricarbonyl-nitrilotriacetic acid - This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer | 03-17-2011 |
| 20110060036 | Branched Multifunctional Nanoparticle Conjugates And Their Use - Disclosed herein are compounds and compositions including a polyglycerol nanocarrier, a therapeutic agent or imaging agent, and optionally a targeting agent. In certain aspects the disclosed compounds include biocompatible hyperbranched polymer nanocarriers. Such compounds and compositions are useful for the targeted delivery of antitumor agents and imaging agents to tumors in vivo. Methods are also disclosed for detecting and treating such tumors. | 03-10-2011 |
| 20110033382 | Imaging Agents - This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[18F]FACPC and (1R,2R) anti-2-[18F]FACPC. | 02-10-2011 |
| 20110028985 | CONDUIT DEVICE AND SYSTEM FOR IMPLANTING A CONDUIT DEVICE IN A TISSUE WALL - Various embodiments of the present invention provide a conduit device including an attaching device configured for defining a helical pathway through a tissue wall and complementary ring in cooperation for securing the device within an aperture defined in the tissue wall. Some embodiments of the present invention further provide a system for implanting a conduit device in a tissue wall. More specifically, some embodiments provide a system including a coring device for defining an aperture in a tissue by removing and retaining a tissue core and securely implanting a conduit device therein so as to provide fluid communication between a first and second surface of the tissue wall via the conduit device. | 02-03-2011 |
| 20110028418 | USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS | 02-03-2011 |
| 20100330602 | Use of Soluble Galectin-3 (Gal-3) for Cancer Treatment - The present invention provides a method for preventing or treating cancer or tumorgenesis disorder comprising administering a prevention or treatment effective amount of a p53 mediated secretome component, such as Gal-3, to a patient in need thereof, thereby preventing or treating cancer or tumorgenesis disorders. Compositions and methods useful for modulating the secretome, including Gal-3, of a cell, comprising increasing extracellular levels of Gal-3, p53 expression, or expression of a downstream effector of p53, in the cell are also provided. Furthermore, methods for identifying tumor targets, diagnostic or prognostic indicators, and therapeutic strategies comprising determining extracellular levels of secreted proteins or secretomes, including Gal-3 are also provided. The present invention provides a novel tumor suppressive mechanism of p53 involving paracrine induction of apoptosis through extracellular Gal-3 levels. The invention also provides evidence that cancer cells are more susceptible to the treatment than normal cells, suggesting augmented expression of the receptor component to Gal3. | 12-30-2010 |
| 20100304996 | B CELL SIGNATURE ASSOCIATED WITH TOLERANCE IN TRANSPLANT RECIPIENTS - The present invention provides methods for predicting the development of tolerance to a transplant, such as a kidney, using molecular markers that have different expression patterns in tolerant transplant recipients, as compared to non-tolerant or healthy, non-recipient controls. | 12-02-2010 |
| 20100286705 | VASCULAR ACCESS TO EXTRA-VASCULAR SPACE - Provided are methods for accessing tissue in the vicinity of a blood vessel. Also provided are devices for use in a lumen of a patient's organ and methods for shunting interior volumes of organs. | 11-11-2010 |
| 20100279969 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 resistance mutants including HIV-1 | 11-04-2010 |
| 20100249172 | 9-CHLORO NOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-Chloro-nos, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-chloro-nos, and methods of preparation and use thereof are disclosed. 9-Chloro-nos is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-Chloro-nos can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-chloro-nos is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 09-30-2010 |
| 20100249122 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof - The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors. | 09-30-2010 |
| 20100227878 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. Representative analogs include the 9-nitro, 9-bromo-, 9-iodo-, and 9-fluoro-noscapines, which bind tubulin and induce apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. Surprisingly, treatment with one of the analogs, 9-nitro-nos, at doses as high as 100 μM, did not affect the cell cycle profile of normal human fibroblasts. This selectivity for cancer cells represents a unique edge over the other available antimitotics. The compounds can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, the compounds are novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 09-09-2010 |
| 20100189762 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 07-29-2010 |
| 20100168052 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 07-01-2010 |
| 20100160296 | USE OF IMIPRAMINE BLUE AND ANALOGS THEREOF IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 06-24-2010 |
| 20100130381 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS - The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations at the S68 codon of HIV-RT, e.g., S68del, are provided. | 05-27-2010 |
| 20100119490 | Therapeutic Use of CD31 Expressing Cells - As described below, the present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells. | 05-13-2010 |
| 20100087907 | Apparatus And Methods For Treating The Aorta - An endovascular stent and an aortic valve replacement can be used to treat the aorta. An endovascular stent suitable for treating the ascending aorta includes a circumferential wall with one or more portions configured to allow blood to flow therethrough, and one or more portions configured to be substantially impermeable. In one version, the blood-permeable portion is defined by bare metal with fenestrations defined therein, and the impermeable portion is formed from polymeric material. The permeable and impermeable portions of the stent are sized, shaped, and located so that, when positioned in the blood vessel to be treated, the impermeable portion is in operative proximity to an aneurysm, dissection, or other area to be treated, and the permeable, bare metal portion is in operative proximity to other blood vessels which need to receive blood from the blood vessel being treated. An aortic valve replacement includes multiple flanges that can be seated in the sinuses of valsalva. The stent or aortic valve replacement may be included in a suitable apparatus for treatment of the aorta. The apparatus for treating the aorta may include a delivery system adapted to be inserted through the apex of the left ventricle of the heart. | 04-08-2010 |
| 20090325920 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 12-31-2009 |
| 20090325881 | MODIFIED FACTOR VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 12-31-2009 |
| 20090311194 | METHODS AND COMPOSITIONS FOR THE PRODUCTION AND USE OF MAGNETOSOMES - Methods and compositions for using magnetosomes as cellular contrast agents and markers for magnetic resonance imaging are provided. Certain methods involve synthesizing magnetosomes in a cell as directed by a nucleotide construct comprising an exogenous polynucleotide sequence, wherein the magnetosome serves as a contrast agent or marker for magnetic resonance imaging. Methods of synthesizing and isolating magnetosomes for introduction into immune-matched cells within a tissue or subject for use as a contrast agent or marker for magnetic resonance imaging are also provided. Also provided are methods for stably transfecting cells to express a polypeptide that drives or modulates magnetosome production in the cell, cells produced by such methods and methods for their isolation, transgenic animals comprising at least one eukaryotic cell produced by such methods, and vectors and delivery systems for the transfection of such cells. Further provided are methods for non-invasively generating a visible image of a tissue or subject containing at least one cell such transfected cell, as well as use of such methods to monitor the location, migration, or proliferation of cells in a tissue or subject or to detect or monitor gene expression in a tissue or subject. | 12-17-2009 |
| 20090306035 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest - Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic formulations comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided. | 12-10-2009 |
| 20090296998 | Assessing Tumor Response to Therapy - Systems, methods and computer program products identify first biologic data in a region of interest in a first image and calculate a first biologic volume histogram from the first biologic data. Second biologic data in the same region of interest is identified in a second image and a second biologic volume histogram is calculated from the second biologic data. A difference in intensity for the region of interest is determined using the first biologic volume histogram and the second biologic volume histogram. | 12-03-2009 |
| 20090276187 | Evaluating Magnetic Resonance Spectra - Provided are methods, systems and computer program products evaluating magnetic resonance (MR) signals from a sample. The methods and systems can be used to evaluate MR signals from various constituents (e.g., metabolites, macromolecules) of the sample. | 11-05-2009 |
| 20090270329 | METHODS OF ADMINISTERING PORCINE B-DOMAINLESS FVIII - The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively. | 10-29-2009 |
| 20090259099 | IMAGE-BASED CONTROL SYSTEMS - Image-based control systems and methods automate the adjustment of medical devices. An image based-control system for an endoscope can include, in addition to the endoscope, a processing system and an actuator. The processing system can receive an image from an image capture device of the endoscope. Based on coordinates of a lumen in the image, the processing system can instruct the actuator to reorient the capture device to direct the capture device toward the lumen. The actuator can be coupled to a manual controller of the endoscope, such that the actuator can reorient the capture device via the manual controller. An image-based control method can include receiving an image from the capture device of the endoscope; identifying coordinates of a lumen in the image; mapping such coordinates to a physical position of the lumen relative to the capture device; and instructing an actuator to adjust an orientation of the endoscope. | 10-15-2009 |
| 20090240041 | TUMOR IMAGING COMPOUNDS - The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of α-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. In addition the compounds can be labeled with technetium and rhenium isotopes using known chelation complexes. The amino acid compounds disclosed herein have a high specificity for target sites when administered to a subject in vivo. The labeled amino acid compounds are useful as imaging agents in detecting and/or monitoring tumors in a subject by Positron Emission Tomography (PET) and Single Photon Emission Computer Tomography (SPECT). | 09-24-2009 |
| 20090221544 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL - The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury. | 09-03-2009 |
| 20090217402 | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF PEPTIDASES IN MACROPHAGE AND MACROPHAGE-LIKE CELLS - Methods and compositions are provided for modulating the activity of macrophage and macrophage-like cells, particularly by modulating the peptidase activity of such cells. In certain aspects, methods are provided for enhancing or suppressing the immune function of a host by increasing or decreasing, respectively, expression of a target peptidase in host macrophage and macrophage-like cells. Such methods for enhancing or suppressing the immune function of a host by increasing or inhibiting (suppressing or silencing) expression of a target peptidase in host macrophage and macrophage-like cells find use in methods for treating and/or preventing a number of diseases and conditions, including cancer, viral and/or bacterial infection, Alzheimer's disease, tissue transplant rejection, autoimmune diseases, and chronic inflammatory diseases. The invention also provides compositions and research tools related to these methods, including vectors for increasing or inhibiting the expression of a peptidase in macrophage and macrophage-like cells, macrophage and macrophage-like cells transfected with these vectors, genetically modified mice that over-express a target peptidase or in which expression of a target peptidase has been disrupted, and selective modulators of peptidase activity in macrophages as well as methods for identifying and using such modulators. | 08-27-2009 |
| 20090208533 | NEISSERIA MENINGITIDIS SEROGROUP A CAPSULAR POLYSACCHARIDE ACETYLTRANSFERASE, METHODS AND COMPOSITIONS - Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A | 08-20-2009 |
| 20090196831 | NANOSTRUCTURES, METHODS OF SYNTHESIZING THEREOF, AND METHODS OF USE THEREOF - A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a magnetic iron oxide nanoparticle, a hydrophobic protection structure including at least an amphiphilic copolymer, wherein the hydrophobic protection structure encapsulates the magnetic iron oxide nanoparticle, and at least one amino-terminal fragment (ATF) peptide or epidermal growth factor receptor (EGFR) antibody conjugated to the amphiphilic copolymer. | 08-06-2009 |
| 20090181397 | PREDICTIVE AND DIAGNOSTIC METHODS FOR CANCER - The present disclosure encompasses methods of diagnosing the presence of a cancer, and particularly a cancer of prostate or breast tissue, in a human subject, predicting the outcome or severity of the disease and methods of reversing the prostate cell transformation based on the presence or absence in the human subject of a dinucleotide (TT) deletion in the gene encoding the U50 snoRNA. Provided, therefore, are methods of identifying a genetic marker of a human subject indicating a cancerous tissue in the human subject, embodiments of the methods comprising: determining from an isolated nucleic acid sample the genotype of the human subject with respect to a locus encoding a snoRNA U50, where a mutation within the nucleotide sequence encoding a snoRNA U50, when compared with a wild-type nucleotide sequence encoding a snoRNA U50, identifies in the human subject a genetic marker associated with a cancer in the human subject. The cancer may be, but is not necessarily limited to, a prostate cancer or a breast cancer. | 07-16-2009 |
| 20090176745 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 07-09-2009 |
| 20090130034 | RE-ENGINEERED UV DAMAGE ENDONUCLEASE, COMPOSITIONS AND METHODS - Provided are methods and compositions for reducing damage to skin by ultraviolet light and other agents that cause distortion to double stranded DNA and methods for reducing damage to other organs due to such DNA distortion. These compositions comprise a novel truncated UV damage endonuclease (a truncated derivative of Uvde 1 (UVDE, Uvelp) of | 05-21-2009 |
| 20090123365 | Multifunctional nanostructures, methods of synthesizing thereof, and methods of use thereof - A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a nanospecies, a hydrophobic protection structure including at least one compound selected from a capping ligand, an amphiphilic copolymer, and combinations thereof, wherein the hydrophobic protection structure encapsulates the nanospecies, and at least one histidine-tagged peptide or protein conjugated to the hydrophobic protection structure, wherein the at least one histidine-tagged peptide or protein has at least one binding site. | 05-14-2009 |
| 20090023791 | PH-dependent NMDA receptor antagonists - NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chrounic pain, vascular dementia and glioma rumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Prefebably the compounds provided herein are allosteric NMDA inhibitors. | 01-22-2009 |
| 20090018167 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states - The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis. | 01-15-2009 |
| 20080318914 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 12-25-2008 |
| 20080280846 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS - A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a β-L- or β-D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient. | 11-13-2008 |
| 20080280294 | Inherited Mitochondrial Dna Mutations in Cancer - A method is provided for identifying a subject likely to have, or at risk of developing a disease condition correlated with increased reactive oxygen species (ROS), including cancer, by identifying in the subject a missense mutation in a nucleic acid of Complex III, IV and/or V of the OXPHOS system. This invention also provides a method of identifying a likelihood of having a heritable predisposition to cancer by detecting a homoplasmic missense mutation in non-tumor tissue of an OXPHOS system gene. This invention also provides a method for detecting likelihood of having cancer, predisposition to cancer, and likelihood of passing a predisposition to cancer to progeny involving identifying in non-tumor tissue of the subject a missense mutation in a complex III, IV and/or V gene of the mitochondrial OXPHOS system. The mutation may be a nuclear or mitochondrial mutation. The invention has been exemplified with respect to prostate cancer. When the mutation is homoplasmic in non-tumor tissue this is an indication it is an inherited and inheritable trait, and that the subject is likely to pass on the mutation to her progeny in the case of mutations in mitochondrial DNA or his or her progeny in the case of mutations in nuclear DNA. Both homoplasmic and heteroplasmic mutations in non-tumor tissue can indicate the presence of cancer. | 11-13-2008 |
| 20080268445 | Ant2 Conditional Knockout Mouse and Methods - Described are methods for inactivating adenine nucleotide transporter proteins in specific tissues of a transgenic nonhuman animal using a conditional knockin/knockout technology such as the Cre-LoxP, Flip-FLP recombinase, or Tet-on/off technologies. Specifically, the Ant2 gene is functionally inactivated in a mouse in liver, with or without the concurrent inactivation of the Ant1 gene. The result is an animal in which the Ant2 gene and accompanying ANT 2 protein is absent in one or more tissues, either in the presence or absence of the Ant1 gene and accompanying protein. The resulting animals, cells, mitochondria, and subcelluar fractions such as the mitochondrial permeability transition pore can then be used to identify agents that affect animal and/or subcellular function via a direct or indirect interaction with the ANT2 protein and/or its Ant2 gene. | 10-30-2008 |
| 20080268013 | Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons - Poly(ethylene oxide) (PEO) glycodendrimers can serve as multivalent inhibitors of selectin-mediated leukocyte recruitment regulating inflammatory response. Disclosed are compounds and methods relating to functionalized branched glycopolymers. In embodiments, the compounds are capable of modifying cell adhesion events and inflammatory conditions. In a particular embodiment, a multi-arm PEO polymer with sulfated lactose end groups can specifically inhibit interactions involving L-selectin. Also disclosed are methods of synthetic preparation and use. | 10-30-2008 |
| 20080241807 | Apparatuses and Methods for Simulating Microlaryngeal Surgery - Apparatus for simulating microlaryngeal surgery. In one embodiment, the apparatus includes a larynx model that emulates an actual larynx, the larynx model including an inner passage that includes a vocal fold model support that emulates a portion of an actual vocal fold, and a vocal fold model that emulates tissues of an actual vocal fold, the vocal fold model being adapted to be received by the vocal fold model support of the larynx model. | 10-02-2008 |
